Table 1. Clinical features of DLBCL-IV patients.

Patient No.	Age	Sex	Disturbance of consciousness	Hepato-megaly	Spleno-megaly	Hemopha-gocytosis	Peripheral blood involvement	WBC (×102/μl)	Hb (g/dl)	PLT (×104/μl)	LD (U/l)	Ferritin (ng/ml)	sIL-2R (U/ml)	Treatment	Outcome from onset (months)
1	62	M	+	-	-	-	-	29	11.2	3.7	261	815	1,420	R+CVP	Dead, 2
2	76	F	+	-	-	NE	-	61	11.2	27.1	590	NE	469	R	Dead, 6
3	81	F	-	-	-	+	-	44	7.9	18.4	284	854	1,830	R+CVP	Relapse in nasal cavity as DLBCL, 24 Alive, 52
4	78	F	-	-	+	+	+	37	7.0	7.3	994	830	1,540	R-THP-COP	Relapse, 12 and 24 Dead, 25
5	77	M	-	-	+	-	-	128	6.3	4.2	1,385	1,360	37,583	R-THP-COP	Alive, 20
6	75	F	-	+	+	+	-	83	8.4	1.8	860	699	3,870	VP-16	Dead, 2.5
7	72	M	-	-	+	+	-	83	10.1	5.8	496	361	2,160	None	Dead, 1.5*
8	68	M	-	-	+	+	-	56	11.0	4.6	763	29,070	11,600	None	Dead, 1.5
9	69	F	+	+	+	+	-	49	10.1	2.0	496	1,637	22,250	None	Dead, 6
10	77	F	+	+	+	+	-	39	11.0	2.8	2,018	22,932	13,003	None	Dead, 0.4
11	83	M	+	-	-	+	-	45	12.9	12.4	440	NE	722	None	Dead, 1.3

Abbreviations: COP, cyclophosphamide, vincristine, prednisolone; CVP, cyclophosphamide, vincristine, prednisone; DLBCL-IV, diffuse large B-cell lymphoma with significant intravascular invasion; Hb, hemoglobin; LD, lactate dehydrogenase; NE, not examined; PLT, platelet; R, rituximab; sIL-2R, soluble interleukin-2 receptor; THP, tetrahydropyranyl adriamycin; VP-16, etoposide; WBC, white blood cell.

Normal range. WBC 33-86×10²/μl, Hb 13.7-16.8 g/dl (male) and 11.6-14.8 g/dl (female), PLT 15.8-34.8×10⁴/μl, LD 124-222 U/l, Ferritin (male) 39-265 ng/ml (male) and ≤ 55 ng/ml (female), sIL-2R 145-519 U/ml.

*Patient 7 underwent breast tumor resection 17 months before his death, and a diagnosis of DLBCL with no intravascular invasion was made.